EMD Serono Reports Results of Bavencio (avelumab) in P-III (JAVELIN Bladder 100) Trial as 1L Maintenance Treatment for Advanced Urothelial Carcinoma
Shots:
- The P-III (JAVELIN Bladder 100) trial evaluates Bavencio + BSC vs BSC alone in patients with LA or metastatic UC
- The results of an exploratory analysis with 19 additional follow-up data from the initial primary analysis, patients showed an overall survival benefit @38mos. median follow-up, m-OS (23.8mos. vs 15.0mos.), 43.7% vs 33.5% were alive @30mos.
- In patients with PD-L1+ tumors, m-OS (30.9mos. vs 18.5mos.), 51.3% vs 38.5% were alive @30mos. & the safety profile was consistent with the overall clinical development program with no new safety signals. In the primary population of all randomized patients,19.5% received ≥2yrs. of treatment & 10.2% discontinuing due to TRAEs @ ≥12mos.
Ref: Businesswire | Image: EMD Group
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com